Previous studies have found a connection between psychiatric problems and post-hematopoietic stem-cell transplantation (HSCT) complications. We sought to evaluate the effect of sertraline on engraftment time, hospitalization period, mortality, and post-transplantation complications in HSCT recipients with depression and/or anxiety. We recruited adults aged 18–60, who were candidates for autologous or allogeneic HSCT with major depression and/or anxiety disorder. They were administered 50 mg of sertraline or placebo daily for the first week, and then 100 mg for the following seven weeks. We documented occurrence and severity of early post-HSCT complications, including infection, mucositis, nausea and vomiting, diarrhea, pain, renal toxicities and liver complications, acute graft-versus-host disease, and veno-occlusive disease, as well as time to engraftment, length of hospitalization and 6-month mortality. Overall, 56 patients participated in the study (sertraline group n = 30, placebo group n = 26). Of the complications, only mortality and readmission up to 6 months post-transplantation were significantly higher in the placebo group compared to sertraline group (P values = 0.040, 0.028, respectively). There were no significant differences for other complications between the groups. Mean engraftment time was significantly lower in the sertraline group (P value = 0.048). This study provides evidence that sertraline positively influences engraftment time, readmission, and mortality after HSCT.
This is a preview of subscription content, log in to check access.
This study was supported by the Shahid Beheshti University of Medical Sciences, Tehran, Iran. The authors thank all staff of Taleghani Hospital and all patients for helping and participating in the study.
All authors have been contributed significantly to this study as follow: MM designed the study, collected the data and edited the article draft. MTA designed the study, analyzed the data and edited the article draft. RK collected and analyzed the data, and wrote the article draft. All authors approved the final article draft. The authors declare that they have no conflict of interest.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Report on state of the art in blood and marrow transplantation. CIBMTR Newsletter. 2007.Google Scholar
Gregurek R, Labar B, Mrsic M, Batinic D, Ladika I, Bogdanic V, et al. Anxiety as a possible predictor of acute GVHD. Bone Marrow Transplant. 1996;18:585–9.PubMedGoogle Scholar
Pereira DB, Christian LM, Patidar S, Bishop MM, Dodd SM, Athanason R, et al. Spiritual absence and 1-year mortality after hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2010;16:1171–9.CrossRefPubMedGoogle Scholar
McGregor BA, Syrjala KL, Dolan ED, Langer SL, Redman M. The effect of pre-transplant distress on immune reconstitution among adult autologous hematopoietic cell transplantation patients. Brain Behav Immun. 2013;30(Suppl):S142–8.CrossRefPubMedGoogle Scholar
Sullivan KM, Mori M, Sanders J, Siadak M, Witherspoon RP, Anasetti C, et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant. 1992;10(Suppl 1):127–34.PubMedGoogle Scholar
Hoodin F, Uberti JP, Lynch TJ, Steele P, Ratanatharathorn V. Do negative or positive emotions differentially impact mortality after adult stem cell transplant? Bone Marrow Transplant. 2006;38:255–64.CrossRefPubMedGoogle Scholar
Loberiza FR Jr, Rizzo JD, Bredeson CN, Antin JH, Horowitz MM, Weeks JC, et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol. 2002;20:2118–26.CrossRefPubMedGoogle Scholar
Prieto JM, Atala J, Blanch J, Carreras E, Rovira M, Cirera E, et al. Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation. J Clin Oncol. 2005;23:6063–71.CrossRefPubMedGoogle Scholar
Lee SJ, Loberiza FR, Antin JH, Kirkpatrick T, Prokop L, Alyea EP, et al. Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:77–83.CrossRefPubMedGoogle Scholar
Molassiotis A, van den Akker OB, Boughton BJ. Perceived social support, family environment and psychosocial recovery in bone marrow transplant long-term survivors. Soc Sci Med. 1997;44:317–25.CrossRefPubMedGoogle Scholar
Tschuschke V, Hertenstein B, Arnold R, Bunjes D, Denzinger R, Kaechele H. Associations between coping and survival time of adult leukemia patients receiving allogeneic bone marrow transplantation: results of a prospective study. J Psychosom Res. 2001;50:277–85.CrossRefPubMedGoogle Scholar
Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98:1594–600.CrossRefPubMedGoogle Scholar
Tegg EM, Griffiths AE, Lowenthal RM, Tuck DM, Harrup R, Marsden KA, et al. Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28:929–33.CrossRefPubMedGoogle Scholar
Andrykowski MA, Bruehl S, Brady MJ, Henslee-Downey PJ. Physical and psychosocial status of adults one-year after bone marrow transplantation: a prospective study. Bone Marrow Transplant. 1995;15:837–44.PubMedGoogle Scholar
Prieto JM, Saez R, Carreras E, Atala J, Sierra J, Rovira M, et al. Physical and psychosocial functioning of 117 survivors of bone marrow transplantation. Bone Marrow Transplant. 1996;17:1133–42.PubMedGoogle Scholar
Tavakoli-Ardakani M, Mehrpooya M, Mehdizadeh M, Hajifathali A, Abdolahi A. Association between interleukin-6 (IL-6), interleukin-10 (IL-10) and depression in patients undergoing hematopoietic stem cell transplantation. Int J Hematol Oncol Stem Cell Res. 2015;9:80–7.PubMedPubMedCentralGoogle Scholar
Raj A. Overview and treatment of social anxiety disorder. Manag Care. 2004;13:52–7.PubMedGoogle Scholar
Weilburg JB. An overview of SSRI and SNRI therapies for depression. Manag Care. 2004;13:25–33.PubMedGoogle Scholar
Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther. 2009;86:527–32.CrossRefPubMedGoogle Scholar
Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol. 2007;2007:76396.CrossRefPubMedGoogle Scholar
Taraz M, Khatami MR, Dashti-Khavidaki S, Akhonzadeh S, Noorbala AA, Ghaeli P, et al. Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial. Int Immunopharmacol. 2013;17:917–23.CrossRefPubMedGoogle Scholar
MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001;7:1–24.CrossRefPubMedGoogle Scholar
Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S. The hospital anxiety and depression scale (HADS): translation and validation study of the Iranian version. Health Qual Life Outcomes. 2003;1:14.CrossRefPubMedPubMedCentralGoogle Scholar
National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.03.: NIH publication; 14 June. 2010.Google Scholar
Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–64.CrossRefPubMedGoogle Scholar
Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol. 1993;66:77–80.CrossRefPubMedGoogle Scholar
Grulke N, Larbig W, Kachele H, Bailer H. Pre-transplant depression as risk factor for survival of patients undergoing allogeneic haematopoietic stem cell transplantation. Psychooncology. 2008;17:480–7.CrossRefPubMedGoogle Scholar
Frick E, Motzke C, Fischer N, Busch R, Bumeder I. Is perceived social support a predictor of survival for patients undergoing autologous peripheral blood stem cell transplantation? Psychooncology. 2005;14:759–70.CrossRefPubMedGoogle Scholar
Horikawa H, Kato TA, Mizoguchi Y, Monji A, Seki Y, Ohkuri T, et al. Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1306–16.CrossRefPubMedGoogle Scholar
Baharav E, Bar M, Taler M, Gil-Ad I, Karp L, Weinberger A, et al. Immunomodulatory effect of sertraline in a rat model of rheumatoid arthritis. NeuroImmunoModulation. 2012;19:309–18.CrossRefPubMedGoogle Scholar
Sitges M, Gomez CD, Aldana BI. Sertraline reduces IL-1beta and TNF-alpha mRNA expression and overcomes their rise induced by seizures in the rat hippocampus. PLoS One. 2014;9:e111665.CrossRefPubMedPubMedCentralGoogle Scholar
Knight JM, Moynihan JA, Lyness JM, Xia Y, Tu X, Messing S, et al. Peri-transplant psychosocial factors and neutrophil recovery following hematopoietic stem cell transplantation. PLoS One. 2014;9:e99778.CrossRefPubMedPubMedCentralGoogle Scholar
Byron JW. Evidence for a β-adrenergic receptor initiating DNA synthesis in haemopoietic stem cells. Exp Cell Res. 1972;71:228–32.CrossRefPubMedGoogle Scholar
Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124:407–21.CrossRefPubMedGoogle Scholar